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abstract
PURPOSEHead and neck squamous cell carcinoma (HNSCC) incidence is high in South America, where recent
data on survival are sparse. We investigated themain predictors of HNSCC survival in Brazil, Argentina, Uruguay,
and Colombia.
METHODS Sociodemographic and lifestyle information was obtained from standardized interviews, and clini-
copathologic data were extracted from medical records and pathologic reports. The Kaplan-Meier method and
Cox regression were used for statistical analyses.
RESULTS Of 1,463 patients, 378 had a larynx cancer (LC), 78 hypopharynx cancer (HC), 599 oral cavity cancer
(OC), and 408 oropharynx cancer (OPC). Most patients (55.5%) were diagnosed with stage IV disease, ranging
from 47.6% for LC to 70.8% for OPC. Three-year survival rates were 56.0% for LC, 54.7% for OC, 48.0% for
OPC, and 37.8% for HC. In multivariable models, patients with stage IV disease had approximately 7.6 (LC/HC),
11.7 (OC), and 3.5 (OPC) times higher mortality than patients with stage I disease. Current and former drinkers
with LC or HC had approximately 2 times higher mortality than never-drinkers. In addition, older age at diagnosis
was independently associated with worse survival for all sites. In a subset analysis of 198 patients with OPC with
available human papillomavirus (HPV) type 16 data, those with HPV-unrelated OPC had a significantly worse 3-
year survival compared with those with HPV-related OPC (44.6% v 75.6%, respectively), corresponding to
a 3.4 times higher mortality.
CONCLUSION Late stage at diagnosis was the strongest predictor of lower HNSCC survival. Early cancer detection
and reduction of harmful alcohol use are fundamental to decrease the high burden of HNSCC in South America.
JCO Global Oncol 6:486-49 . © 2020 by American Society of Clinical Oncology
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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC)
incidence is high in South America, with higher
rates in Argentina, Brazil, French Guyana, and
Uruguay.1 The main risk factors for HNSCC con-
tinue to be smoking and alcohol consumption, 2
potentially modifiable lifestyle factors. However,
high-risk human papillomavirus (HPV) infection
has become an important risk factor for a subset of
HNSCC, mostly in the oropharynx.2 In the United
States, where aggressive tobacco control programs
have resulted in reduced tobacco use, a marked
decline in the incidence rates of larynx cancer
(LC), hypopharynx cancer (HC), and oral cavity
cancer (OC) has been observed over the past 3
decades. In the same period, the incidence of
HPV-related oropharynx cancer (OPC) has increased
substantially.3 In South America, the prevalence of
HPV-related OPC seems to be much lower than
that in the United States (60%) or Europe (31%).
The reported prevalence of HPV-related OPC has
been reported to be as low as 4% in Sao Paulo,
Brazil.4
Despite progress in diagnostic procedures and ther-
apeutic management, survival after HNSCC diagno-
sis remains relatively low in Europe5,6 and North
America,7 whereas recent survival data are scarce in
South America. In this study, we aimed to examine
the survival of patients with HNSCC in several South
American institutions and investigate the influence of























We used data prospectively collected from the Inter-
CHANGE study, a multicenter case-control study that was
initiated to investigate the risk factors for HNSCC onset and
outcomes. Patients were followed up to investigate the
main predictors of survival after HNSCC. The International
Agency for Research on Cancer (IARC; Lyon, France) was
responsible for the overall coordination of the study, which
included 8 institutions from the following 4 countries:
Argentina, Brazil, Colombia, and Uruguay. Data from
Argentina were mostly from the Angel Roffo Institute of
Oncology (Buenos Aires; public health system), with a few
patients from the Italiano Hospital (Buenos Aires; private).
Data from Brazil are from the following 4 centers: National
Cancer Institute (INCA) in Rio de Janeiro (public), Araujo
Jorge Hospital in Goiania (private), A.C. Camargo Cancer
Center in Sao Paulo (private), and Santa Rita de Cassia
Hospital in Vitoria (private). Uruguay was represented by
the Dr Manuel Quintela Hospital in Montevideo (public),
whereas data from Colombia were obtained from the Santa
Fé de Bogotá University Hospital (Bogotá; private).
Inclusion criteria included age≥ 18 years and a diagnosis of
a primary HNSCC from 2011 to 2017. HNSCCwas classified
according to the International Classification of Diseases for
Oncology, third edition,8 and included LC (C32.0-C32.9), HC
(C12.9 and 13C.0-13C.9), OC (C00.3-C00.9, C02.0-C02.3,
C03.0-C03.9, C04.0-C04.9, C05.0, and C06.0-C06.9), and
OPC (C01.0-C01.9, C02.4, C05.1-C05.2, C09.0-C09.9, and
C10.0-10.9). All tumors were confirmed by histology.
Explanatory Variables
All patients participated in a standardized interview conducted
within 6 months of diagnosis, during which information on
sociodemographic, lifestyle, and clinical factors was collected.
Sociodemographic variables included residence at time of
recruitment, sex (male or female), age at diagnosis (≤ 50, 51-
60, 61-70, or ≥ 71 years), education level (categorized as
illiterate, fundamental incomplete, fundamental complete,
medium complete, or superior), and self-identified race or
ethnicity (white, black, mulatto, or other/unknown). Mulattos
are considered to be people of mixed African and European
descent. As a result of small numbers, Asians, indigenous,
andmestizo (mixed indigenous and European descent people
from Colombia) patients were grouped in the race or ethnicity
category of other.
Lifestyle variables included comprehensive tobacco and
alcohol histories. Tobacco use included cigarettes, cigars,
and pipes, and the following 3 aspects were investigated:
overall smoking history (never-smoker, former smoker, or
current smoker), (2) smoking duration (categorized as
never, 1-39, or ≥ 40 years), and (3) smoking intensity
(categorized as never, , 30, or ≥ 30 pack-years). Alcohol
intensity was examined as overall alcohol history (never-
drinker, former drinker, or current drinker) and alcohol
intensity (categorized as≤ 2 or. 2 drinks per day). Alcohol
use included all types of alcohol, such as cachaça, vodka,
whisky, tequila, rum, gin, beer, and wine.
Clinicopathologic data were obtained from medical records
and pathologic reports. Stage at diagnosis was based on the
seventh edition of the TNM classification of the American
Joint Committee on Cancer (AJCC)9 and classified into four
categories (stage I-IV). Institutions from Buenos Aires,
Goiania, and Vitoria provided additional information on
HPV-16 E6 serology (a highly specific biomarker of HPV-16
infection) for patients with OPC, which corresponded to
nearly 50% of patients with OPC. Patients with high
seroreactivity (mean fluorescent intensity, ≥ 1,000) were
considered to have HPV-related OPC.10
Follow-Up
The primary outcome was overall survival, which was
measured from the date of HNSCC diagnosis until death
from any cause, the end of the study (June 31, 2018), or
loss to follow-up, whichever occurred first. Patients con-
tribute person-years of follow-up from their date of di-
agnosis to the date of death, loss to follow-up, or end of
study. Therefore, there was a maximum of 7.5 years of
CONTEXT
Key Objective
What are the main predictors of survival in patients with head neck squamous cell carcinoma (HNSCC) from South America?
Knowledge Generated
Three-year survival for HNSCC is low in South America, especially for patients with oropharynx and hypopharynx cancer. Late
stage at diagnosis is a strong independent predictor of worse survival for all HNSCC sites. Former and current drinkers
diagnosed with laryngeal or hypopharyngeal cancers had over two-fold increased hazard of death compared with never
drinkers.
Relevance
Early cancer detection and reduction of harmful alcohol use need to be prioritized to reduce the high burden of HNSCC in
South America.
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follow-up (January 1, 2011, to June 31, 2018). Information
on vital status was obtained via routine follow-up visits and/
or by linking the patient’s data with vital statistics, cancer
registry files, and medical records, depending on the
available sources at each center. IARC provided an online
database to enter follow-up information. For the main
analysis, we assumed that a patient was lost to follow-up
when he or she could not be tracked by any source of
information in the last 24 months of the study completion.
Statistical Analyses
Analyses were performed separately by anatomic cancer
site. Because of the relatively small sample size, patients
with HC were pooled with patients with LC for multivariable
regression analysis. We estimated the probability of 3-year
survival using the Kaplan-Meier method and compared
differences in survival curves across strata for each variable
using the log-rank test.
To evaluate the association between survival and the ex-
planatory variables, we used hazard ratios (HRs) and
95% CIs estimated by means of Cox proportional hazards
models. Variables included in the models were those that
had an a priori hypothesized or previously observed as-
sociation with HNSCC survival based on a review of the
literature. These include age and stage at diagnosis, sex,
education, race or ethnicity, and smoking and alcohol
histories. Univariable and multivariable models (including
all variables) were fitted. All multivariable models were
adjusted for calendar year of diagnosis (categorized as
2011-2013 and 2014-2017) and center to account for
possible changes in therapeutic management over time
and different treatment approaches, respectively. The
model with combined LC and HC was additionally adjusted
for tumor site as a result of the potential differences in
prognosis between the 2 types of cancer. The model for
OPC also included HPV status because differences in
prognosis between HPV-related and HPV-unrelated OPC
have been reported.
The proportional hazards assumption, assessed by ex-
amining log-log survival plots and Schoenfeld residuals,
was met for all variables in the multivariable models.
Likelihood ratio tests were used to obtain overall P values for
each variable in the multivariable models, considering
comparison with the model excluding the variable in
question. A small amount of data was missing for some
explanatory variables, and all analyses were restricted to
patients with complete data on all variables used in the
multivariable models, thus assuming that the data were
missing completely at random. All statistical analyses were
performed using Stata 14.2 statistical software (StataCorp,
College Station, TX). A 2-sided P , .05 was considered
statistically significant.
Ethics Approval
The InterCHANGE study was approved by the ethical re-
view boards of the IARC and of each participating center. All
patients provided written informed consent for their par-
ticipation in this study.
RESULTS
From 2011 through 2017, a total of 1,829 patients newly
diagnosed with HNSCC were enrolled in the InterCHANGE
study. Patients with missing (n = 18), overlapping (n =
101), or “other” (n = 65) topography codes and those with
missing (n = 100) or inconsistent date of known last vital
status (at or before date of diagnosis, n = 7) were excluded
from the study. Less than 5% of patients (n = 75) had
missing data for ≥ 1 of the explanatory variables and were
excluded. The proportions of individuals with missing data
were 3.1% for stage, 1.5% for education, 0.4% for smoking
history, and 0.5% for alcohol history. The proportion of
patients lost to follow-up was 17.4%.
Analyses were based on 1,463 patients with a complete set
of information. Of these patients, 378 (25.8%) had LC, 78
(5.3%) had HC, 599 (40.9%) had OC, and 408 (27.9%)
had OPC. Most patients were from Brazil (n = 1,174,
80.3%), followed by Argentina (n = 228, 15.6%), Uruguay
(n = 32, 2.2%), and Colombia (n = 29, 2.0%). Approxi-
mately 55.5% of patients were diagnosed with stage IV
tumors, varying from 47.6% for LC to 70.8% for OPC. The
baseline characteristics of the participants are listed in
Table 1.
By the end of the follow-up period, 672 patients (45.9%)
had died, and the median follow-up time was 1.7 year
(range, 0.1-6.9 years). On the basis of Kaplan-Meier an-
alyses, 3-year survival was estimated to be highest for LC
(56.0%; 95% CI, 50.3% to 61.2%) and OC (54.7%; 95%
CI, 50.3% to 58.9%), intermediate for OPC (48.0%; 95%
CI, 42.4% to 53.3%), and lowest for HC (37.8%; 95% CI,
25.9% to 49.6%). On the basis of the log-rank test, worse
survival was associated with advanced stage at diagnosis
(Fig 1), lower education (OC and OPC), smoking (OC and
OPC), alcohol consumption (LC and OPC), male sex (OPC),
and older age at diagnosis (OPC; Appendix Table A1).
For LC andHC combined, univariable analyses showed that
advanced stage at diagnosis and alcohol consumption were
associated with higher mortality rates. The mortality hazard
in patients with HC was 1.7 times that in patients with LC
(Table 2). In multivariable-adjusted models, the hazard for
mortality was higher among older patients (≥ 71 v ≤ 50
years: HR, 1.73; 95% CI, 0.99 to 3.02), mulattos (v
whites: HR, 1.44; 95% CI, 1.02 to 2.02), those with ad-
vanced stage (IV v I: HR, 7.62; 95% CI, 3.49 to 16.64), and
ever-drinkers (current v never: HR, 2.27; 95% CI, 1.36 to
3.77; and former v never: HR, 2.06; 95% CI, 1.24 to 3.41).
After multivariable adjustment, the mortality hazard in
patients with HC was approximately 1.6 times that in pa-
tients with LC (HR, 1.57; 95% CI, 1.08 to 2.30; Table 2).
For patients with OC, univariable analyses revealed that
advanced stage at diagnosis, lower education level, and
smoking history were associated with higher mortality rates
Abrahão et al
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(Table 3). In multivariable-adjusted models, mortality
hazards were significantly higher among patients age
≥ 61 years (61-70 v ≤ 50 years: HR, 1.46; 95% CI, 0.99 to
2.14; and ≥ 71 v ≤ 50 years: HR, 1.82; 95% CI, 1.18 to
2.78) and those with advanced-stage disease (IV v I: HR,
11.7; 95% CI, 6.09 to 22.43; Table 3).
Among patients with OPC, univariable analyses showed
that older age, male sex, lower education, advanced stage
at diagnosis, ever-smoker status, and ever-drinker status
were associated with higher mortality rates (Table 4). After
adjustment, mortality rates remained higher among men
(v women: HR, 1.84; 95% CI, 1.08 to 3.14), patients age
≥ 61 years (61-70 v ≤ 50 years: HR, 2.17; 95% CI, 1.36 to
3.46; and ≥ 71 v ≤ 50 years: HR, 2.97; 95% CI, 1.68 to
5.24), and patients with advanced-stage disease (IV v I:
HR, 3.49; 95% CI, 1.53 to 7.99; Table 4). In a subset
analysis of 198 patients with OPC with available HPV-16
status (48.5% of all patients with OPC), 3-year survival was
lower among patients with HPV-unrelated versus HPV-
related OPC (44.6% v 75.6%, respectively; Fig 2). Pa-
tients with HPV-unrelated OPC had a mortality rate
3.4 times that of patients with HPV-related OPC after
multivariable adjustment (HR, 3.35; 95% CI, 1.33 to 8.45;
Table 4).
Similar associations betweenmortality and smoking duration
and intensity and alcohol intensity were observed when
compared with overall histories for all cancer sites (Appendix
Table A2). When we performed an analysis restricted to
centers with . 100 patients (INCA in Rio de Janeiro, A.C.
Camargo Cancer Center in São Paulo, Santa Rita de Cassia
in Vitória, Araújo Jorge in Goiania, and Angel Roffo in Buenos
Aires; total of 1,400 patients), 3-year survival did not differ
substantially from results across centers.
DISCUSSION
The InterCHANGE study provided relevant information on
the predictors of survival after larynx, hypopharynx, oral
cavity, and oropharynx squamous cell carcinoma using up-
to-date information (2011-2017) from 8 centers in 4
countries in South America. Three-year overall survival was
, 50% for HC and OPC and slightly. 50% for LC and OC.
Late stage at diagnosis was a strong independent predictor
of worse survival for all HNSCC sites. Other predictors of





















































46 35 28 21 13 7 0II
94 76 53 38 25 12 2III
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Time After Diagnosis (years)
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102 89 67 49 33 14 2
No. at risk:
I
111 82 59 45 24 16 2
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FIG 1. Overall survival by stage at diagnosis of head and neck squamous cell carcinoma for each anatomic site in the InterCHANGE study (2011-2017).
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sites, alcohol consumption (former or current drinkers) for
LC/HC, male sex and low education level for OPC, and
mulatto race/ethnicity for LC/HC. In addition, in a subset
analysis, HPV-unrelated OPC was associated with signifi-
cantly inferior survival compared with HPV-related OPC.
The proportion of stage IV HNSCCs was strikingly high (56%)
in our cohort. If we combine stages III and IV, approximately
75% of patients were diagnosed at later stages. HNSCC
diagnosis includes clinical and pathologic information.11
Although immunohistochemical HPV testing has prognos-
tic significance, this test is not currently mandatory to make
therapeutic decisions for patients with OPC not included in
deintensification trials.10 Reasons for late HNSCC diagnosis
in South America are often multifactorial and may include
TABLE 2. Relation of Sociodemographic and Clinical Factors to the Hazard of Death for Larynx and Hypopharynx Cancers Combined
Factor
Larynx and Hypopharynx Cancers (n = 456)
No. of Patients Univariable HR (95% CI) P a Multivariable HRb (95% CI) P a
Age at diagnosis, years .2960 .0270
≤ 50 54 Reference Reference
51–60 161 0.89 (0.56 to 1.42) 0.87 (0.53 to 1.43)
61–70 152 1.17 (0.74 to 1.85) 1.29 (0.79 to 2.12)
≥ 71 89 1.22 (0.74 to 2.01) 1.73 (0.99 to 3.02)
Sex
Male 399 1.38 (0.88 to 2.17) .1467 1.07 (0.65 to 1.75) .7888
Female 57 Reference Reference
Race/ethnicity .0223 .0111
White 288 Reference Reference
Black 35 1.37 (0.85 to 2.19) 1.42 (0.84 to 2.41)
Mulatto 121 1.23 (0.91 to 1.67) 1.44 (1.02 to 2.02)
Other/unknown 12 0.17 (0.02 to 1.23) 0.13 (0.02 to 0.99)
Stage at diagnosis , .0001 , .0001
I 61 Reference Reference
II 55 3.49 (1.46 to 8.35) 3.53 (1.45 to 8.59)
III 108 4.59 (2.08 to 10.17) 4.60 (2.05 to 10.32)
IV 232 7.63 (3.56 to 16.32) 7.62 (3.49 to 16.64)
Education level .1325 .7191
Superior 27 Reference Reference
Medium complete 53 1.17 (0.51 to 2.69) 0.99 (0.42 to 2.33)
Fundamental complete 76 1.33 (0.61 to 2.89) 0.87 (0.39 to 1.95)
Fundamental incomplete 261 1.80 (0.88 to 3.68) 1.11 (0.53 to 2.32)
Illiterate 39 1.44 (0.63 to 3.32) 0.82 (0.32 to 2.14)
Smoking history .0939 .3129
Never-smoker 44 Reference Reference
Former smoker 173 1.66 (0.94 to 2.93) 1.72 (0.94 to 3.18)
Current smoker 239 1.77 (1.02 to 3.10) 1.66 (0.91 to 3.01)
Alcohol history .0007 .0029
Never-drinker 74 Reference Reference
Former drinker 183 2.04 (1.28 to 3.27) 2.06 (1.24 to 3.41)
Current drinker 199 2.27 (1.43 to 3.61) 2.27 (1.36 to 3.77)
Tumor site .0028 .0219
Larynx 378 Reference Reference
Hypopharynx 78 1.71 (1.23 to 2.39) 1.57 (1.08 to 2.30)
Abbreviation: HR, hazard ratio.
aLikelihood ratio test.
bAdjusted for all variables in the table plus center and calendar year of diagnosis.
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lack of awareness of cancer signs and symptoms (in both
patients andhealth care providers), lack of access to appropriate
health care, and shortage of medical resources as a result of
fragmented health systems.12-14 Nearly half of the participants in
our study (n = 677, 46.3%) were treated at public hospitals,
where patients frequently face a significant delay in cancer
diagnosis.15 Whenever a delay in diagnosis occurs, the potential
curability ofHNSCCdecreases considerably.12,16 Importantly, we
found that stage at diagnosis was strongly associated with worse
survival for all HNSCCsites, regardless of the center of treatment.
Although not directly comparable, results from the
United States and Europe also show a high proportion of
advanced-stage disease (regional or distant) at diagnosis.
For instance, data from the American Cancer Society
showed that, during 2007-2013, 66% of patients with OC
and OPC were diagnosed with advanced disease.17 In
Europe, a study that investigated survival after HNSCC from
86 cancer registries during 1999-2007 revealed that 54%
of patients were diagnosed at an advanced stage (regional
or metastatic).6 These results highlight the unmet need of
TABLE 3. Relation of Sociodemographic and Clinical Factors to the Hazard of Death for Oral Cavity Cancer
Factor
Oral Cavity (n = 599)
No. of Patients Univariable HR (95% CI) P a Multivariable HRb (95% CI) P a
Age at diagnosis, years .5702 .0114
≤ 50 110 Reference Reference
51-60 188 1.05 (0.73 to 1.51) 1.03 (0.71 to 1.50)
61-70 167 1.17 (0.81 to 1.68) 1.46 (0.99 to 2.14)
≥ 71 134 1.28 (0.87 to 1.88) 1.82 (1.18 to 2.78)
Sex .3293 .6497
Male 441 1.15 (0.86 to 1.53) 1.09 (0.75 to 1.57)
Female 158 Reference Reference
Race/ethnicity .1659 .1048
White 366 Reference Reference
Black 57 1.05 (0.69 to 1.57) 0.90 (0.58 to 1.39)
Mulatto 161 1.20 (0.92 to 1.58) 1.10 (0.82 to 1.47)
Other/unknown 15 0.36 (0.09 to 1.46) 0.25 (0.06 to 1.06)
Stage at diagnosis , .0001 , .0001
I 95 Reference Reference
II 102 2.31 (1.11 to 4.82) 2.41 (1.15 to 5.04)
III 111 4.59 (2.32 to 9.09) 4.97 (2.49 to 9.90)
IV 291 9.27 (4.90 to 17.56) 11.7 (6.09 to 22.43)
Education level .0205 .2103
Superior 39 Reference Reference
Medium complete 91 1.49 (0.74 to 3.01) 0.88 (0.42 to 1.83)
Fundamental complete 104 1.97 (1.00 to 3.90) 1.16 (0.56 to 2.39)
Fundamental incomplete 295 1.81 (0.95 to 3.44) 1.01 (0.50 to 2.01)
Illiterate 70 2.72 (1.36 to 5.46) 1.56 (0.73 to 3.36)
Smoking history .0478 .1864
Never-smoker 121 Reference Reference
Former smoker 175 0.83 (0.57 to 1.21) 0.63 (0.38 to 1.05)
Current smoker 303 1.18 (0.85 to 1.64) 0.73 (0.44 to 1.23)
Alcohol history .1918 .3217
Never-drinker 131 Reference Reference
Former drinker 211 1.03 (0.73 to 1.46) 0.96 (0.59 to 1.55)
Current drinker 257 1.27 (0.92 to 1.77) 1.19 (0.74 to 1.92)
Abbreviation: HR, hazard ratio.
aLikelihood ratio test.
bAdjusted for all variables in the table plus center and calendar year of diagnosis.
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early HNSCC diagnosis, not only in South America but also
in several high-income countries.
We observed that older age at diagnosis was independently
associated with lower survival for all cancer sites, consistent
with previous studies in Europe5 and North America.18
Relevant factors that influence HNSCC prognosis among
elderly patients are the presence and severity of comor-
bidities and therapeutic approaches. Relevant comor-
bidities include cardiovascular and respiratory diseases,
which are strongly associated with smoking and alcohol
consumption.19 These comorbidities likely contribute to
treatment decisions.20,21 Although older patients with
TABLE 4. Relation of Sociodemographic and Clinical Factors to the Hazard of Death for Oropharynx Cancer
Factor
Oropharynx (n = 408)
No. of Patients Univariable HR (95% CI) P a Multivariable HRb (95% CI) P a
Age at diagnosis, years
≤ 50 83 Reference .0009 Reference .0008
51-60 159 1.74 (1.14 to 2.66) 1.69 (1.09 to 2.61)
61-70 118 2.04 (1.31 to 3.17) 2.17 (1.36 to 3.46)
≥ 71 48 2.58 (1.56 to 4.28) 2.97 (1.68 to 5.24)
Sex .0016 .0168
Male 345 1.98 (1.24 to 3.14) 1.84 (1.08 to 3.14)
Female 63 Reference Reference
Race/ethnicity .9761 .9981
White 246 Reference Reference
Black 42 1.05 (0.68 to 1.63) 0.97 (0.60 to 1.58)
Mulatto 102 1.01 (0.73 to 1.40) 1.02 (0.71 to 1.47)
Other/unknown 18 1.18 (0.55 to 2.54) 1.00 (0.33 to 2.96)
Stage at diagnosis , .0001 , .0001
I 18 Reference Reference
II 33 0.97 (0.36 to 2.62) 1.21 (0.44 to 3.32)
III 68 1.31 (0.54 to 3.18) 1.86 (0.75 to 4.64)
IV 289 2.43 (1.08 to 5.50) 3.49 (1.53 to 7.99)
Education level , .0001 .0252
Superior 40 Reference Reference
Medium complete 38 0.65 (0.28 to 1.52) 0.79 (0.32 to 1.94)
Fundamental complete 72 1.88 (1.00 to 3.55) 1.96 (0.96 to 3.99)
Fundamental incomplete 221 2.30 (1.30 to 4.09) 1.99 (1.02 to 3.88)
Illiterate 37 2.09 (1.05 to 4.16) 1.83 (0.81 to 4.13)
Smoking history .0009 .0747
Never-smoker 46 Reference Reference
Former smoker 148 2.07 (1.12 to 3.81) 1.32 (0.67 to 2.59)
Current smoker 214 2.67 (1.47 to 4.85) 1.87 (0.92 to 3.79)
Alcohol history .0001 .5638
Never-drinker 46 Reference Reference
Former drinker 173 3.34 (1.79 to 6.24) 1.41 (0.65 to 3.02)
Current drinker 189 2.84 (1.52 to 5.33) 1.24 (0.58 to 2.67)
HPV16 status; subset analysis of 198 patientsc .0003 .0058
Positive 33 Reference Reference
Negative 165 3.32 (1.53 to 7.21) 3.35 (1.33 to 8.45)
Abbreviations: HPV, human papillomavirus; HR, hazard ratio.
aLikelihood ratio test.
bAdjusted for all variables in the table plus center and calendar year of diagnosis.
cHPV16 E6 serology data from Vitoria, Goiania, and Buenos Aires (Angel Roffo).
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HNSCC may have limited capacity to endure multi-
modality treatment (surgery, chemotherapy, and/or ra-
diotherapy), a US study showed that elderly patients with
advanced disease who received multimodality treatment
had better survival than older patients who received
single-modality therapy.18 A careful assessment of risk
and potential benefit of different treatment approaches is
crucial to decrease HNSCCmortality andmorbidity among
elderly patients.
We observed higher mortality rates among ever-smokers
with OPC in the univariable analysis, but this association
was attenuated after adjustment for covariates. For patients
with LC or HC, alcohol consumption was significantly as-
sociated with lower survival. Current and former drinkers
had approximately 2.3 and 2.1 times higher mortality rates,
respectively, compared with never-drinkers. The small
difference between former and current drinkers may be
partially related to cumulative years of drinking. Mortality
rates were also higher among drinkers with OPC, although
the association was attenuated after adjustment for con-
founders. Our findings are similar to those from a recent
study in Uruguay,22 which found alcohol use to be an in-
dependent predictor of worse survival for HNSCC. Alcohol
consumption has also been associated with lower survival
in patients with HNSCC in a number of studies in North
America,23 Asia,24 and Europe.25 In Latin America, harmful
alcohol consumption is a major health problem and one of
the leading risk factors for cancer, indicating a need for
stronger policies to decrease alcohol misuse.26
Our study supports the role of HPV as a prognostic factor for
OPC, with patients with HPV-related OPC experiencing
better survival than patients with HPV-unrelated cancer,
consistent with preceding studies in Europe and North and
South America.27,28 Given the significant epidemiology
changes in OPC observed over the past few decades,
studies looking at the potential benefit of primary prevention
(HPV vaccination) and secondary prevention (screening for
oral HPV infection) are warrented.29
This study was limited because we lacked data on patient
comorbidities, as well as detailed information on treatment
approaches by stage at diagnosis. Because data were
collected on patients diagnosed before 2018, we did not
use the AJCC 8th edition staging system, which was fully
implemented in January 2018. Consequently, we could not
evaluate changes in staging classification, particularly for
OPC. In addition, at the time of this study, tissue biomarkers
for OPC (such as p16 expression) were not available, and
this will be the subject of a future research project. How-
ever, several studies have demonstrated that HPV-16 E6
antibody is a highly specific biomarker for HPV positivity
with false-positive rates, 1%.10,30-32 Data were missing for
some explanatory variables. A complete-records analysis
was used, which assumes that data are missing completely
at random. Deviations from this assumption could result in
bias in the estimated associations. However, , 5% of in-
dividuals were excluded as a result of missing covariate
data; therefore, it is unlikely that this had a significant
impact on the results. The extent to which our cohort is
representative of patients with HNSCC in South America is
unclear, and additional studies including more South
American centers are warranted to confirm our findings.
The InterCHANGE project has major strengths. This study
represents a multicollaborative research effort to provide
actual information on a disease with great mortality and
morbidity. We obtained recent (2011-2017), good-quality,
prospective data from several hospitals specializing in
cancer treatment in South America, providing relevant
findings to the literature, where data are scarce. Our study
followed a standardized protocol, with all cancers con-
firmed by histology. We had nearly complete information on
stage at diagnosis, which is a strong predictor of HNSCC
outcome and is often missing in epidemiologic studies. We
collected detailed information on tobacco and alcohol use,
which are modifiable risk factors that not only cause
HNSCC but also have been associated with cancer prog-
nosis. In addition, we provided information on patients’ race
or ethnicity and education level, allowing us to account for
social determinants of health, elements that may greatly
influence early diagnosis and cancer survival.33
In summary, 3-year survival after HNSCC diagnosis was low
in the South American centers we studied, especially for
OPC and HC. Elderly patients had higher mortality rates,
which highlights the need of careful assessment of risk and
potential benefit of therapeutic management. Our findings
of worse survival among former and current drinkers di-
agnosed with LC or HC emphasize the need for health
policies aimed at decreasing alcohol consumption in the
population. This is especially relevant in light of a recent
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FIG 2. Three-year overall survival (and 95% CI) from oropharynx
cancer by human papillomavirus (HPV) type 16 status in the In-
terCHANGE study (2011-2017).
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a systematic analysis of 195 countries that showed that the
total attributable burden of alcohol use was greater than
demonstrated in previous studies. Moreover, cancer, in-
cluding HNSCC, accounted for a substantial proportion of
total alcohol-attributable deaths.34 Finally, late stage at
diagnosis was the strongest predictor of HNSCC survival.
Efforts to detect cancer at an earlier stage are fundamental
to improve survival after HNSCC in South America.
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APPENDIX
TABLE A1. Three-Year OS After Head and Neck Squamous Cell Carcinoma by Anatomic Site in the InterCHANGE Study (2011-2017)
Factor
Larynx (n = 378) Hypopharynx (n = 78) Oral Cavity (n = 599) Oropharynx (n = 408)
3-Year OS (95% CI) P a 3-Year OS (95% CI) P a 3-Year OS (95% CI) P a 3-Year OS (95% CI) P a
Overall 56.0 (50.3 to 61.2) 37.8 (25.9 to 49.6) 54.7 (50.3 to 58.9) 48.0 (42.4 to 53.3)
Period of diagnosis .4676 .3649 .5233 .0572
2011-2013 54.5 (48.0 to 60.6) 34.7 (21.0 to 48.8) 55.4 (50.1 to 60.3) 44.6 (38.0 to 51.0)
2014-2017 61.0 (49.5 to 70.7) 43.7 (21.5 to 64.1) 53.6 (45.4 to 61.2) 56.4 (46.5 to 65.1)
Age at diagnosis, years .1707 .3990 .5658 .0013
≤ 50 65.2 (45.7 to 79.1) 43.0 (19.8 to 64.4) 57.0 (46.4 to 66.2) 61.3 (48.6 to 71.7)
51-60 60.1 (50.5 to 68.4) 39.5 (18.8 to 59.6) 55.8 (48.0 to 63.0) 48.5 (39.7 to 56.8)
61-70 52.9 (43.3 to 61.7) 25.6 (8.0 to 48.0) 53.0 (44.6 to 60.7) 41.7 (31.2 to 51.9)
≥ 71 49.1 (36.2 to 60.8) 45.4 (17.8 to 69.7) 53.6 (43.9 to 62.4) 36.7 (21.9 to 51.5)
Sex .0980 .4294 .3347 .0033
Male 54.5 (48.4 to 60.1) 39.0 (26.4 to 51.4) 53.7 (48.5 to 58.5) 44.7 (38.7 to 50.5)
Female 65.8 (49.6 to 78.0) 30.0 (4.4 to 62.8) 57.8 (49.1 to 65.5) 67.1 (52.6 to 78.1)
Race/ethnicity .2300 .1912 .2285 .9747
White 57.6 (50.5 to 64.0) 47.0 (29.1 to 63.0) 56.5 (50.8 to 61.7) 48.5 (41.3 to 55.3)
Black 42.4 (22.8 to 60.8) 29.6 (5.2 to 60.7) 53.2 (38.6 to 65.8) 47.1 (30.3 to 62.3)
Mulatto 53.3 (42.3 to 63.1) 17.3 (4.5 to 36.9) 49.6 (41.1 to 57.5) 48.1 (37.3 to 58.1)
Other/unknown 100.0 80.0 (20.4 to 96.9) 81.5 (43.5 to 95.1) 41.3 (12.7 to 68.5)
Education level .1680 .2242 .0201 .0002
Superior 61.4 (35.3 to 79.5) —b 70.5 (52.0 to 82.9) 62.8 (43.2 to 77.3)
Medium complete 77.7 (59.8 to 88.4) 23.3 (3.6 to 52.9) 61.9 (50.5 to 71.4) 76.4 (58.2 to 87.5)
Fund complete 56.5 (41.5 to 69.0) 60.6 (29.2 to 81.6) 51.4 (40.5 to 61.2) 52.6 (39.6 to 64.0)
Fundamental incomplete 52.1 (44.9 to 58.8) 31.0 (16.4 to 46.9) 55.2 (48.9 to 61.1) 37.8 (30.3 to 45.2)
Illiterate 53.3 (33.3 to 69.7) 43.8 (11.9 to 72.6) 37.9 (25.4 to 50.5) 50.2 (32.5 to 65.6)
Stage at diagnosis , .0001 .7142 , .0001 .0002
I 90.4 (78.5 to 95.9) —b 91.6 (83.1 to 95.9) 71.1 (39.6 to 88.2)
II 65.9 (48.2 to 78.8) 45.7 (11.0 to 75.7) 76.1 (65.6 to 83.8) 76.5 (56.6 to 88.1)
III 59.7 (48.3 to 69.4) 33.3 (10.9 to 58.0) 58.6 (48.2 to 67.5) 62.9 (48.9 to 74.1)
IV 40.4 (32.6 to 48.1) 36.8 (22.8 to 51.0) 33.8 (27.9 to 39.7) 39.3 (32.9 to 45.7)
Smoking status .2052 .4812 .0511 .0022
Never 69.7 (49.5 to 83.1) 54.9 (18.7 to 80.6) 58.4 (48.4 to 67.1) 73.4 (55.6 to 85.0)
Former 54.1 (45.1 to 62.3) 31.4 (12.4 to 52.6) 61.3 (53.0 to 68.6) 50.8 (41.7 to 59.1)
Current 55.0 (47.0 to 62.2) 37.7 (22.4 to 52.9) 49.8 (43.7 to 55.7) 41.0 (33.4 to 48.4)
Drinking status .0034 .7691 .1885 .0004
Never 75.5 (62.5 to 84.6) 40.0 (5.2 to 75.3) 60.9 (51.3 to 69.2) 75.4 (58.9 to 86.0)
Former 53.4 (44.2 to 61.7) 40.5 (24.1 to 56.3) 59.6 (52.2 to 66.3) 39.1 (30.8 to 47.2)





Positive NA NA NA 75.6 (55.4 to 87.6)
Negative NA NA NA 44.6 (35.8 to 53.0)
Abbreviations: HPV, human papillomavirus; HR, hazard ratios; NA, not applicable; OS, overall survival.
aLog-rank test P value.
bLess than 3 years of follow-up.
cHPV16 E6 serology data from Vitoria, Goiania, and Buenos Aires (Angel Roffo).
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TABLE A2. Association of Smoking and Alcohol Duration and Intensity to Mortality in the InterCHANGE Study (2011-2017)
Factor
Larynx and Hypopharynx Oral Cavity Oropharynx
Multivariable HRa (95% CI) P b Multivariable HRa (95% CI) P b Multivariable HRa (95% CI) P b
Tobacco duration
Never Reference .3343 Reference .2006 Reference .0720
, 30 years 1.66 (0.84 to 3.29) 0.61 (0.36 to 1.06) 1.20 (0.59 to 2.46)
≥ 30 years 1.38 (0.77 to 2.46) 0.68 (0.40 to 1.15) 1.77 (0.89 to 3.53)
Tobacco pack-years
Never or , 1 Reference .5347 Reference .0649 Reference .3959
1-39 1.37 (0.77 to 2.45) 0.61 (0.39 to 0.96) 1.35 (0.74 to 2.48)
≥ 40 1.33 (0.76 to 2.33) 0.57 (0.36 to 0.92) 1.50 (0.81 to 2.78)
Alcohol intensity
Never Reference .0013 Reference .9803 Reference .7383
≤ 2 drinks per day 2.01 (1.15 to 3.51) 0.95 (0.57 to 1.58) 1.26 (0.58 to 2.75)
. 2 drinks per day 2.31 (1.42 to 3.76) 0.95 (0.58 to 1.56) 1.36 (0.61 to 3.00)
Abbreviation: HR, hazard ratio.
aEach covariate was assessed in separate models adjusted for sex, age, stage at diagnosis, race/ethnicity, education, center, calendar year of
diagnosis, and alcohol and/or smoking histories (never, former, or current), as appropriate.
bLikelihood ratio test.
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